Suchergebnisse - "Zhu, Hong-Hu"

PubPharm (201)

21

Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia

enthalten in: Annals of hematology | 2023

von Chang, J. | Shen, Y. | Shi, T. | +3

22

At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database

enthalten in: Cancers | 2023

von Yin, X. | Wang, R. | Shen, H. | +2

23

Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia : A single‐arm, multicentre, phase 2 trial

enthalten in: British Journal of Haematology | 2023

von Xie, M. | Lu, Y. | Ouyang, G. | +27

24

Chemotherapy with the use of next‐generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

enthalten in: Cancer | 2023

von Xie, M. | Shi, T. | Jiang, Q. | +5

25

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes : A retrospective single‐center study

enthalten in: Hematological Oncology | 2023

von Mei, C. | Ye, L. | Ren, Y. | +12

26

Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2022

von Cheng, W. | Li, J. | Zhu, Y. | +23

27

APL : Nemo finds its sea anemone

enthalten in: Blood | 2022

von Wang, Q. | Zhu, H.

CommentOn: Blood. 2022 Dec 1;140(22):2358-2370. - PMID 35984905

28

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

enthalten in: ResearchSquare.com | 2022

von Shen, Y. | Zhang, Y. | Chang, J. | +5

29

An Effective and Chemotherapy-free Strategy of All-trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia in All Risk Groups

enthalten in: ResearchSquare.com | 2022

von Wang, H. | Gong, S. | Li, G. | +17

30

An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)

enthalten in: Blood cancer journal | 2022

von Wang, H. | Gong, S. | Li, G. | +17